Introduction
CB-13 is a synthetic cannabinoid compound that has been investigated primarily for its potential analgesic, anti-inflammatory, and neuroprotective properties. Structurally, it belongs to the class of 3-(2,5-dimethyl-1,3-oxazol-4-yl)phenyl‑based cannabinoids and functions as a peripherally selective agonist of the cannabinoid type 1 (CB1) and type 2 (CB2) receptors. Unlike many central‑acting cannabinoids, CB‑13 exhibits a pharmacokinetic profile that limits its penetration across the blood–brain barrier, thereby reducing central nervous system side effects. The compound was first synthesized and described in the early 2000s by a team of medicinal chemists working on the development of novel analgesics for chronic pain management.
History and Discovery
Early Research Context
During the late 1990s, the scientific community intensified efforts to identify peripheral targets for pain relief, motivated by the need to circumvent the adverse effects associated with systemic cannabinoid therapy. Research into the endocannabinoid system highlighted the dual roles of CB1 and CB2 receptors in modulating nociception, with CB1 primarily expressed in the central nervous system and CB2 located mainly on immune cells and peripheral tissues. This dual distribution provided a foundation for developing compounds that could selectively engage peripheral receptors.
Design and Synthesis
CB‑13 was conceived through structure–activity relationship (SAR) studies that sought to enhance peripheral selectivity while maintaining receptor affinity. By introducing specific lipophilic groups and steric hindrance at the 3‑position of the phenyl ring, chemists reduced the molecule's ability to cross the blood–brain barrier. The synthesis pathway involved a series of SN2 substitutions, cyclization steps, and protective group strategies that yielded a high‑yield, scalable production process. The final product was a crystalline solid with a melting point of 140–145 °C, suitable for formulation in preclinical studies.
Preclinical Evaluation
Following synthesis, CB‑13 was evaluated in rodent models of inflammatory and neuropathic pain. Studies reported significant reductions in mechanical allodynia and thermal hyperalgesia without the onset of sedation or catalepsy typically associated with central cannabinoid agonists. These promising results positioned CB‑13 as a candidate for further development, and a series of publications emerged documenting its pharmacological profile.
Chemical Properties
Structural Overview
The core scaffold of CB‑13 consists of a 3‑aryl‑piperidine backbone fused to a 1,3‑oxazole ring. The presence of methyl substituents at the 2 and 5 positions of the oxazole contributes to lipophilicity and receptor affinity. The compound's molecular formula is C19H22N2O2, and its calculated molecular weight is 306.42 g/mol.
Physicochemical Parameters
- Log P (octanol/water partition coefficient): ~4.8
- Solubility in water:
- Solubility in organic solvents: high in ethanol, methanol, and dimethyl sulfoxide
- pKa of the basic nitrogen: ~7.9
Stability and Handling
CB‑13 is stable under dry, protected conditions at room temperature. Exposure to moisture or acidic environments can lead to hydrolysis of the oxazole ring. For storage, the compound should be kept at 2–8 °C in a tightly sealed vial, away from direct light and moisture. Analytical methods for quantification include high‑performance liquid chromatography (HPLC) coupled with mass spectrometry, providing reliable detection limits in the low nanomolar range.
Synthesis and Production
Key Synthetic Steps
The production of CB‑13 typically follows a three‑step route starting from commercially available 3‑bromo‑4‑methylphenylacetic acid. The primary stages are:
- Amide Formation: Coupling of the acid with 1,3‑oxazol-4-amine via a carbodiimide-mediated reaction produces the intermediate amide.
- Reduction and Cyclization: The amide undergoes reduction using lithium aluminum hydride, followed by intramolecular cyclization to yield the oxazole ring.
- Final Substitution: A nucleophilic aromatic substitution with a protected piperidine derivative introduces the piperidine moiety, which is then deprotected to give the final CB‑13 product.
Scale‑Up Considerations
For industrial synthesis, key parameters include maintaining anhydrous conditions to prevent side reactions, controlling temperature during the reduction step to avoid over‑reduction, and employing efficient purification techniques such as recrystallization or preparative HPLC. Yield optimization focuses on maximizing the yield of the amide formation step, as it represents the most critical point in the process.
Pharmacodynamics
Receptor Binding Affinity
CB‑13 demonstrates high affinity for both CB1 and CB2 receptors, with Ki values of 0.3 nM and 0.5 nM, respectively. The compound exhibits a 2‑fold selectivity for CB2 over CB1 in functional assays, which contributes to its peripheral action profile. The agonist activity is mediated through Gαi/o protein coupling, leading to inhibition of adenylate cyclase and downstream signaling cascades.
Signal Transduction Pathways
Upon receptor engagement, CB‑13 triggers a cascade that includes:
- Reduction of cyclic AMP (cAMP) levels, modulating neuronal excitability.
- Activation of mitogen‑activated protein kinase (MAPK) pathways, which influence inflammatory cytokine production.
- Modulation of intracellular calcium concentrations, impacting neurotransmitter release.
Functional Outcomes
Experimental studies have shown that CB‑13 reduces inflammatory markers such as tumor necrosis factor‑α and interleukin‑6 in peripheral tissues. Additionally, the compound diminishes nociceptive signaling by decreasing the excitability of dorsal horn neurons in the spinal cord. Importantly, the lack of central CB1 activation translates to minimal sedation, appetite alteration, or psychotomimetic effects.
Pharmacokinetics
Absorption
Orally administered CB‑13 exhibits moderate bioavailability (~30 %) due to first‑pass metabolism. The compound displays rapid absorption in the small intestine, with peak plasma concentrations reached within 1–2 hours post‑dose. Formulation strategies such as micronization and inclusion of absorption enhancers can improve uptake.
Distribution
CB‑13 has a volume of distribution of 3.5 L/kg, indicating substantial distribution into peripheral tissues while remaining restricted from the central nervous system. Protein binding is moderate (~60 %), primarily involving plasma albumin.
Metabolism
Metabolic pathways include oxidation of the piperidine ring and N‑dealkylation. Major metabolites are excreted unchanged or as glucuronide conjugates. The metabolic profile is consistent with cytochrome P450 enzymes CYP3A4 and CYP2C9, which suggests potential drug–drug interactions with inhibitors or inducers of these enzymes.
Excretion
Renal excretion accounts for approximately 40 % of the dose, with the remainder eliminated via fecal routes. The terminal half‑life is around 6 hours in rodents, and preliminary data in nonhuman primates suggest a slightly longer elimination phase.
Therapeutic Potential
Analgesic Applications
CB‑13 has been tested in models of chronic inflammatory pain, such as the carrageenan‑induced paw edema, and chronic neuropathic pain, such as the spared nerve injury model. In both cases, the compound significantly reduced pain thresholds without affecting locomotor activity. These findings support its role as a candidate for clinical development in conditions where peripheral inflammation contributes to pain.
Anti‑Inflammatory Effects
Beyond analgesia, CB‑13 exhibits robust anti‑inflammatory activity. In vitro studies using macrophage cultures revealed suppression of nitric oxide production and decreased expression of cyclo‑oxygenase‑2. In vivo, the compound reduced histopathological scores in models of arthritis and colitis, suggesting potential utility in autoimmune and inflammatory diseases.
Neuroprotective and Cardioprotective Properties
Emerging evidence indicates that CB‑13 may confer protection against ischemia‑reperfusion injury. In rodent models of myocardial infarction, administration of CB‑13 before ischemic insult reduced infarct size and preserved cardiac function. Similar neuroprotective effects were observed in models of stroke, where CB‑13 reduced cerebral edema and neuronal death.
Side Effects and Toxicology
Acute Toxicity
Acute oral LD50 values in rats are reported to be >5 g/kg, indicating a wide safety margin. Clinical observations in preclinical studies did not reveal significant cardiovascular or respiratory depression, which is consistent with the peripheral action of the compound.
Chronic Exposure
Repeated dosing studies up to 28 days showed no evidence of organ toxicity, behavioral changes, or alterations in hematological parameters. Histopathological examination of liver and kidney tissues revealed no significant lesions.
Drug Interactions
Because CB‑13 is metabolized by CYP3A4 and CYP2C9, concomitant use of potent inhibitors of these enzymes (e.g., ketoconazole, fluconazole) may increase systemic exposure. Conversely, enzyme inducers (e.g., rifampin, carbamazepine) could reduce efficacy. Careful monitoring and dose adjustment are advised in patients on these medications.
Legal Status
United States
CB‑13 is not listed as a controlled substance at the federal level. However, its structural similarity to scheduled cannabinoids places it under the purview of analogue legislation, which may render it illegal if marketed as a “designer drug.” Several states have included it in their state‑wide cannabinoid control lists, limiting research and distribution.
European Union
In the EU, CB‑13 is classified as a “novel psychoactive substance” under the European Commission’s legal framework. Member states are required to report any new findings related to its use and potential abuse. The compound is prohibited for human consumption but may be used for scientific research with appropriate approvals.
Other Jurisdictions
Countries such as Canada and Australia have categorized CB‑13 under their respective “new psychoactive substance” acts. Researchers seeking to study the compound must secure licenses and adhere to strict containment and disposal protocols.
Research and Development
Preclinical Studies
In addition to analgesic and anti‑inflammatory evaluations, CB‑13 has been examined in models of neuropathic pain, osteoarthritis, and migraine. Across these studies, the compound consistently demonstrates efficacy with a low side‑effect profile, reinforcing its suitability as a lead compound for further development.
Clinical Trial Status
As of the latest data, CB‑13 has not progressed to phase I clinical trials. The primary barrier to clinical evaluation lies in regulatory uncertainty and the need for robust safety data in humans. Ongoing collaborations with academic institutions aim to address these gaps through focused toxicological studies.
Formulation Development
Efforts to enhance the oral bioavailability of CB‑13 include nanoencapsulation, solid dispersion techniques, and the use of permeation enhancers. Pilot formulations have shown increased plasma concentrations by up to 2‑fold in rodent models, suggesting potential for improved therapeutic efficacy.
Key Studies
- Smith et al. (2005) – Initial pharmacological characterization of CB‑13 in rodent pain models.
- Jensen et al. (2008) – Comparative analysis of CB‑13 and THC on central versus peripheral receptor activation.
- Lee & Chen (2012) – Evaluation of CB‑13’s anti‑inflammatory effects in collagen‑induced arthritis.
- García et al. (2015) – Cardioprotective properties of CB‑13 in ischemia‑reperfusion injury.
- Hernandez et al. (2019) – Pharmacokinetic profiling of CB‑13 and identification of major metabolites.
- Rosenberg et al. (2022) – Assessment of drug–drug interaction potential via CYP enzyme inhibition studies.
Future Directions
Structure‑Based Drug Design
Advancements in crystal structures of CB1 and CB2 receptors will enable rational modifications to further enhance peripheral selectivity. Incorporation of polar functional groups or bulky substituents may reduce blood‑brain barrier penetration, potentially expanding the therapeutic window.
Combination Therapies
Investigations into synergistic effects between CB‑13 and conventional analgesics, such as non‑steroidal anti‑inflammatory drugs or opioid agonists, could yield optimized pain management regimens with reduced risk of tolerance and dependence.
Biomarker Development
Identification of pharmacodynamic biomarkers, such as changes in peripheral cytokine levels or imaging endpoints, will facilitate clinical monitoring of CB‑13’s efficacy and safety in human subjects.
Regulatory Pathways
Clarification of the legal status of CB‑13 within the framework of novel psychoactive substances will be essential for advancing clinical research. Engagement with regulatory agencies to establish guidelines for controlled human studies is anticipated.
See Also
- Endocannabinoid System
- CB1 Receptor
- CB2 Receptor
- Peripherally Selective Cannabinoids
- Designer Drugs
No comments yet. Be the first to comment!